References
- Nichols S., Waters W. E., Wheeler M. S. The management of female breast disease by Southampton general practitioners. Br. Med. J. 1980; 281: 1450–53
- William H., Hindle W. H. Other benign breast problems. Clin. Obstet. Gynecol. 1994; 37: 916–24
- FIGO. Benign breast tumors. Breast Pain and Nodularity , K. Dobashi. Valencia, Spain 1994; 225–9
- Maddox P. R., Harrison B. S., Mansel R. E., Hughes L. E. Non-cyclical mastalgia: an improved classification and treatment. Br. J. Surg. 1989; 76: 901–4
- Pye K. S., Mansel E. R., Hughes E. L. Clinical experience of drug treatments for mastalgia. Lancet 1985; ii: 373–8
- Fentiman I. S., Caleffi M. Dosage duration and effect on bone mineral content of tamoxifen treatment for mastalgia. Br. J. Surg. 1988; 75: 845–6
- Mouridsen H., Palshof T., Patterson S., Bat-tersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978; 5: 131–41
- Messinis I. E., Nillius S. S. Comparison between tamoxifen and clomiphene for induction. Acta Obstet. Gynecol. Scand. 1982; 61: 377–9
- Ricciardi I., Iannizuberto A. Tam-oxifen-induced regression of benign breast lesions. Obstet. Gynecol. 1979; 54: 80–4
- Messinis I. E., Lolis D. Treatment of premenstrual mastalgia with tamoxifen. Acta Obstet. Gynecol. Scand. 1988; 67: 307–9
- Reid R. L., Yen S. S. C. Premenstrual syndrome. Am. J. Obstet. Gynecol. 1981; 139: 85–104
- Backstrom T., Carstensen H. Estrogen and progesterone in plasma in relation to premenstrual tension. J, Steroid Biochem. 1974; 5: 257–61
- Halbreich U., Ben-David M., Assael M., Bornstein R. Serum prolactin in woman with premenstrual syndrome. Lancet 1976; 11: 654–6
- Gorodeski G. I., Beery F., Lunenfield B., Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil. Sterii 1992; 57: 320–7
- Fisher B., Constantino J., Redmond L., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R., Margolese R., Robioux A., Shibara H., Terz J., Paterson A. H. G., Feldman M. I., Farrer W., Evans J., Licley H. L., Ketner M. A randomized, clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 1989; 320: 479–84
- Bartlett K., Ermin O., Hutcheon A., Preece P., Scott J. S., Forrest P., Chetty U., Prescott R. J., Rodger A., Smyth J., George D., Habeshaw T., Kaye S. B., McArdle C. S., McCallum M., Smith D. C., McMillan B., Robinson S. M., Stewart H. J., White G. K., Giles G. R. Breast Cancer Trials Committee. Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987; ii: 171–5, 17.
- Eggest-Kruse W., Von Furnier D., Legler V., Sunkermann H. Comparison of danazol with tamoxifen, gestagen, acupuncture, local treatment and placebo: results in 1000 patients:. Benign Breast Disease. , M. Bqum, W. D. George, L. E. Hughes. Royal Society of Medicine, London 1985
- La Vecchia C., Tavani A., Garattini S. Adverse effects of preventive therapy in humans. IARC Sci. Publ 1996; 139: 135–42
- Fisher B., Constantino S. P., Redmond C. K., et al. Endometrial cancerintamoxifen-treated breast cancer patients: findings from the NSABP B-14. J. Nat. Cancer Inst. 1994; 86: 527–37
- Magriples U., Naftolin F., Schwartz P. E., Carcangiu M. L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 1993; 11: 485–90
- Sananes S., Khairallah T., Touboul E., Salat-Baroux J., Uzan S. Surveillance of patients treated with tamoxifen. Presse Med. 1996; 25: 499–502